Lauxera Capital Partners just raised €520 million for its new Lauxera Growth II fund.
The firm announced closing the fund on May 19, which attracted more money than it originally targeted, in less than 18 months. Over 90 per cent of previous investors from the firm’s 2021 medtech/healthtech capital raise returned and put in even more money.
The main goal is to help promising European healthtech and medtech companies grow bigger, especially by expanding into the large American market. Lauxera will invest this money in 12 to 15 companies that already sell products. These firms work in medical devices, digital health, diagnostics and related areas.
“These numbers tell a story,” commented Lauxera partner Edoardo Fracchia, “but the real one is behind them: 90 per cent + LP re-investment rate, a base of sovereign funds, institutions and family offices across three continents and a team that has been quietly building one of Europe’s most focused healthtech growth platforms.”
The typical investment in each ranges from €20 million to €50 million. Companies the firm has backed include German neurovascular device maker Acandis and Swedish imaging company Antaros Medical. This capital will help them launch new products faster and enter the U.S. market more easily.
Since launching its first fund in 2021, Lauxera’s companies have created more than 400 new jobs and introduced dozens of new products, many in the United States. One big success story is British company OrganOx. Lauxera supported it as it grew revenue more than five times and sold the business to Japanese company Terumo Corp (OTCMKTS: TRUMF) (FRA: TUO) for about US$1.5 billion in late 2025.
Medtech and digital health fundraising has grown stronger in the U.S. over the past couple of years. Through the first three quarters of 2025, American digital health startups raised US$9.9 billion — US$1.5 billion more than what was raised in the same period of 2024. The third quarter alone brought in US$3.5 billion, according to Rock Health.
Larger deals are becoming more common, especially for companies using artificial intelligence in healthcare. One such company, Breath Diagnostics, recently raised over US$2.5 million to advance its breath analysis technology for early disease detection. Other notable American medtech fundraises over the past couple of years have included big rounds for Blackrock Neurotech, sleep tech specialist Oura, Kestra Medical Technologies Ltd‘s (NASDAQ: KMTS) wearable defibrillator, Caresyntax’s surgical AI software and Imperative Care’s stroke tech.
Read more: Breath Diagnostics advances pre-op pneumonia screening with FDA breakthrough designation
Follow Rowan Dunne on LinkedIn
rowan@mugglehead.com
